Compare CCLD & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCLD | TTRX |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United States |
| Employees | 3650 | 2 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.0M | 107.2M |
| IPO Year | N/A | N/A |
| Metric | CCLD | TTRX |
|---|---|---|
| Price | $2.38 | $3.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 596.1K | 21.7K |
| Earning Date | 05-07-2026 | 05-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.49 | N/A |
| Revenue Next Year | $7.95 | N/A |
| P/E Ratio | $32.04 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.95 | $2.57 |
| 52 Week High | $4.01 | $5.98 |
| Indicator | CCLD | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 31.45 | 61.38 |
| Support Level | $2.22 | $3.55 |
| Resistance Level | $3.14 | $3.83 |
| Average True Range (ATR) | 0.17 | 0.18 |
| MACD | -0.07 | 0.03 |
| Stochastic Oscillator | 11.16 | 84.27 |
CareCloud Inc delivers flexible, tech-enabled solutions for healthcare providers of all sizes and multi-specialties across the U.S. It is a healthcare technology company offering cloud-based solutions that simplify clinical, administrative, and financial workflows for medical practices of all sizes. Its comprehensive suite includes Electronic Health Records (EHRs), Practice Management, Revenue Cycle Management (RCM), Medical Billing, Telehealth, and Patient Experience solutions. The group helps practices increase efficiency, improve patient care, and drive sustainable growth-all while ensuring HIPAA compliance and seamless integration. The operating segments of the group are Healthcare IT, which is the key revenue-generating segment, and Medical Practice Management.
Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.